

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "IBUPROFEN GRANULES"

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that "Ibuprofen Granules (0.2g)" (the "**Product**") developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has been granted approval by the National Medical Products Administration of the People's Republic of China for passing the consistency of quality and efficacy evaluation of generic drugs (the "**Consistency Evaluation**").

Ibuprofen has analgesic, antipyretic and anti-inflammatory effects, and can be used for relieving mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, dysmenorrhea as well as fever caused by common cold or influenza. The Product is taken by mixing with warm water, making it easier for children taking the drug.

Ibuprofen Granules is one of the key antipyretic and analgesic drugs of the Group, being the first product of this type passing the Consistency Evaluation in China. The passing of the Consistency Evaluation indicates the consistency of the Product with the originator drug in terms of quality and efficacy, providing a medication option of good quality and competitive price for patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 31 October 2019

* For identification purposes only

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.